Click here for the CME evaluation / post-test

Activity Index
Click on the titles below to view the presentations.

Friday, November 16, 2007

Session I: Welcome and introductory lectures

Defining the high-risk patient: Genetics, clinical characteristics and biomarkers
York E. Miller, MD

Efficacies of available behavioral therapies and pharmacotherapies for smoking cessation
Carolyn M. Dresler, MD, MPA

Novel targets and agents for chemoprevention
Scott M. Lippman, MD

Session II: Non-small cell lung cancer (NSCLC)


Increasing sensitivity and specificity by combining invasive strategies with imaging tools
John C. Kucharczuk, MD

Selecting patients for adjuvant chemotherapy: What is state-of-the-art?
Corey J. Langer, MD

Adjuvant radiotherapy for NSCLC
Walter J. Curran, Jr, MD

Session III: Locally advanced NSCLC

Potentially resectable locally advanced NSCLC: Is there a role for surgery?
Harvey I. Pass, MD

Contemporary strategies for optimizing chemotherapy and radiotherapy in patients with unresectable NSCLC
Walter J. Curran, Jr, MD

Emerging role of targeted agents in the locally advanced setting
Karen L. Kelly, MD

The role of radiofrequency ablation in the treatment of lung cancer patients
Damian E. Dupuy, MD

Session IV: Advanced NSCLC

First-line treatment for advanced NSCLC
Helen J. Ross, MD

Customizing chemotherapy and targeted agents for advanced NSCLC with molecular markers
Roman Perez-Soler, MD

Management of the elderly patient and PS2
Paul J. Hesketh, MD

Saturday, November 17, 2007

Session V: Small cell lung cancer (SCLC)


Limited disease: Is there a state-of-the-art?
Michael C. Perry, MD, MS, MACP

Targeted agents for SCLC
Charles M. Rudin, MD, PhD


Session VI: Targeted therapies and immunomodulation


How do we assess targeted agents with chemotherapy: Together, sequentially, or separately?
George R. Blumenschein, Jr,MD

Beyond bevacizumab: Future role of angiogenesis inhibition in NSCLC
Martin J. Edelman, MD

Beyond angiogenesis inhibitors: Evolving role of the other targeted agents
Roger B. Cohen, MD

TLR9 agonists and other immunomodulatory strategies
Vera Hirsh, MD

Update on vaccines
Nevin Murray, MD, FRCPC

Session VII: Surgical controversies in thoracic oncology

Video-assisted thoracic surgical lobectomy
Walter J. Scott, MD, FACS

The role of subanatomic resection for NSCLC
Eric Vallieres, MD, FRCSC

Mediastinal neglect: Why is mediastinal assessment important and how do we contend with patients who have been inadequately staged?
Larry R. Kaiser, MD

Session VIII: Special topics in thoracic oncology

Mesothelioma: How a resistant disease became treatable
Hedy L. Kindler, MD

Thymoma
Tracey Evans, MD

Esophageal cancer
Barbara A. Burtness, MD

Click here for the CME evaluation / post-test